Biotech Values

[genisi]

On "solanezumab is not dead yet" issue

Agree on both your points - there is a small signal, probably not clinically significant but could be disease modifying.
I'm thinking: if the effect correlates with the biomarkers, it would be worth trying another trial perhaps in prodromal AD patients and negotiate with the FDA on using these biomarkers along with cognitive measure as efficacy endpoints.